The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Pfizer Japan Takes Generic Contenders to Court over Lyrica Patent
Pfizer Japan said on August 17 that it has filed a patent infringement suit against a host of generic makers that obtained approval the same day for their copycat versions of the major pain medicine Lyrica (pregabalin). Over more than…
To read the full story
Related Article
- 22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
August 18, 2020
- Pfizer Japan Has Different Interpretation on Lyrica Patent Ruling
July 29, 2020
- Lyrica Expected to Face Generic Onslaught by Year’s End as Patent Ruled Invalid
July 28, 2020
- Sawai and 7 Other Generic Makers Seeking Lyrica Patent Invalidity
February 4, 2019
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…